Bullying Southeast Asia with Tariff Threats

By Jomo Kwame Sundaram and Nadia Malyanah Azman
KUALA LUMPUR, Malaysia, Jul 29 2025 – US President Trump has successfully used tariff threats to achieve economic, political and even personal goals. These threats, reminiscent of colonialism, have secured submission and concessions.

Jomo Kwame Sundaram

<strongIndonesian lessons
After hearing the 2024 US elections, Indonesian President Prabowo Subianto respectfully stood up in his Jakarta office to call to congratulate the winner.

Trump bragged about his tariff offer to Indonesia in mid-July 2025, flattering its president profusely. After hesitating initially, former General Prabowo had agreed to join BRICS, despite Trump’s clear disapproval.

“I spoke to their really great president, very popular, very strong, smart. And we made the deal. We will pay no tariffs…they are giving us access to Indonesia … the other part is they are going to pay 19% and we are going to pay nothing.”

An Indian commentator noted, “Those words say it all. This deal is clearly one-sided, and it should bother the whole world.” Americans, not Indonesians, will pay tariffs on imports from Indonesia.

The US is Indonesia’s second-largest export market, importing apparel, palm oil, footwear, and cosmetics. Initially, Trump had threatened a 32% tariff on such imports.

This has been reduced to 19%, still almost four times more than last year! In 2024, Indonesian exports to the US were taxed at 5% on average. The Indonesian president has not complained but instead seemed relieved.

Nadia Malyanah Azman

Indonesia will lose not only exports, but also growth and jobs. As Trump loves to brag, he added insult to injury as he could not resist reiterating: “They will pay 19%, and we will pay nothing.”

Guaranteed sales
Indonesia will also buy $15 billion of US oil and gas, $4.5 billion of farm produce, and 50 Boeing jets. But the 2019 Lion Air plane tragedy, which the US plane manufacturer quickly blamed on Indonesian pilots, is still alive in the national memory.

Boeing’s reputation worldwide has not recovered from the investigation into the Nairobi air crash involving the same plane model, which led to its grounding.

Indonesia is among the US’s top 25 trade partners. The deal secures American access to the Indonesian market, allowing US goods to be sold tariff-free.

Last year, Indonesia shipped $28 billion worth of goods to the US. Higher tariffs are now expected to cut Indonesian exports by a quarter, GDP growth by 0.3%, and many jobs!

Other Southeast Asian lessons?
The Philippines’ Marcos II government is the most pro-US in Southeast (SE) Asia, hosting 11 American military bases.

Yet it was the only one without a US tariff offer before Secretary of State Rubio’s SE Asian visit earlier this month. The Philippines has since been offered a new US trade deal with the same 19% tariff rate despite its loyalty to Washington.

Loyal long-term support for the US, 11 military bases and serving as an additional ‘unsinkable aircraft carrier’ just south of Taiwan did not secure a better trade deal for the other archipelagic nation in SE Asia.

Trump wants trade deals even more favourable to the US than existing ones. With deadlines passing, the US is expected to announce more trade deals.

The tariff threats have been more effective for Trump, thanks to decades of trade liberalisation forced on the Global South, undermining earlier import-substituting industrialisation and food security measures.

Washington has already revised earlier demands, sometimes not just once, but typically to the chagrin of US trade partners. Vietnam’s Communist Party leader was initially thought to have negotiated a better deal than other SE Asian governments.

Lessons for others?
Will the US offer to Indonesia become a template for others? Or even for countries of comparable significance in the world economy? Nobody knows Trump’s strategy, let alone how it may still change.

Perhaps it begins with the threat of high tariffs, shock and awe. Then, a less painful deal is offered, dressed up as a concession.

This may be worse than the status quo ante, but it still seems preferable to the original threat. Nations will also be required to buy US goods that may not be needed or offer the best value for money.

Thus, US offers to SE Asia are being studied worldwide for lessons on better negotiating with Washington. Meanwhile, the US refuses to negotiate collectively except with the European Union.

All over the world, policymakers will continue to debate Trump’s tariff war strategy after Monday’s agreement in Scotland, which included a 15% baseline tariff on most EU exports to the US.

The US-EU deal makes clear the West, including Europe, has never really been committed to a rules-based international order, including multilateral trade liberalisation.

As American buyers pay the tariffs, imported goods become more expensive. US trading partners will lose exports, related growth and jobs. This will mean less expansion, employment and exports worldwide, accelerating stagnation.

Meanwhile, most SE Asian governments believe they have little choice but to continue negotiating with the US, which is driving them to others willing to engage them on more favourable, if not fairer, terms.

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

When the System Protects Itself, Not People

A woman and child walk through the heavily bombed town of Khuza’a in the Gaza Strip. Credit: UN Women/Samar Abu Elouf

By Stephanie Hodge
NEW YORK, Jul 29 2025 – In Geneva, nearly 600 UN staff based at the UN Office there held an Extraordinary Staff Union meeting on July 24, 2025, passing a unanimous motion of no confidence in the UN80 reform initiative, the Secretary General António Guterres, and Under Secretary General Guy Ryder—with no abstentions and no dissenting voices (source).

Meanwhile, Gaza is being flattened. The war has become the deadliest ever for UN personnel: over 200 UNRWA staff have been killed since October 2023 (UNRWA). At Least 116 Staff Members of United Nations Palestine Refugee Agency Killed in 2024, Bringing Total to 263 Staff Fatalities Since War in Gaza – UN Staff Union Committee – Question of Palestine

Aid starvation is mounting. UN agencies warn Gaza faces mass starvation, with children visibly wasting away and some aid workers joining food lines themselves (Amnesty International). Reports describe scenes of “walking corpses” due to critical shortages of food, water, and medicine (The Times).

As mass starvation spreads across Gaza, our colleagues and those we serve are wasting away – Amnesty International ‘Walking corpses’ haunt Gaza streets: UN says children dying of starvation, India urges emergency relief – The Economic Times

Despite the conditions, famine has not been officially declared—due to access constraints and the politicization of humanitarian data (Associated Press). Experts say Gaza is at risk of famine but haven’t declared one. Here’s why. | AP News

Meanwhile, the UN Office for the Coordination of Humanitarian Affairs (OCHA) confirms collapse of health and water services, especially in Rafah (OCHA Flash Update #165). Hostilities in the Gaza Strip and Israel | Flash Update #165 | United Nations Office for the Coordination of Humanitarian Affairs – Occupied Palestinian Territory

Enter UN80, a sweeping internal reform launched in mid 2025 to mark the UN’s 80th anniversary. Promoted under the veneer of “modernization” and “efficiency,” the plan cuts junior-level positions, consolidates decision-making in the Secretary-General’s office, and accelerates centralization—without transparent evaluation of previous reform cycles or external oversight (IPI Commentary). UN80 and the Reckoning Ahead: Can Structural Reform Deliver Real Change? – IPI Global Observatory

The UN’s own Joint Inspection Unit (JIU) warned in its 2023 report that widespread use of affiliate workers and non-staff consultants had undermined accountability. In earlier reports, the JIU criticized prior reforms for concentrating authority without improving transparency or including field voices. JIU/REP/2023/8

This is not a system in crisis—it’s a system functioning as designed: to protect reputation, manage political risk, and suppress the dissent of its own workforce. It prioritizes control over service, and branding over substance.

Meanwhile, global crises—from Ukraine to Sudan—are exposing the UN’s deepening credibility crisis. A 2022 High-Level Committee on Management (HLCM) report recognized growing internal distrust and institutional fatigue (UN CEB HLCM Report). Microsoft Word – 2211281E.docx

So, what now?

We need truth-tellers inside the system. Staff who document abuses. Analysts who refuse to whitewash data. Leaders who resist sanitizing the truth to please donors. These are the ones who can restore integrity to institutions that have lost their compass.

There is a moral precedent in the figure of Job. He did not suffer because he failed, but because he refused to lie. In the face of collapse, he remained grounded in truth. That refusal—not obedience—is what sustained him.

Not every fight is winnable. But silence?

That’s not an option.

As Martin Luther King Jr. said: “In the end, we will remember not the words of our enemies, but the silence of our friends.”

If the UN is to survive the 21st century, it must retake its soul. That begins with truth. Not PR. Not spin. Truth that costs something.

Stephanie Hodge is an international evaluator and former UN advisor who has worked across 140 countries. She is a former staffer of UNDP 1994-1996 & 1999- 2004 and UNICEF 2008-2014. She writes on governance, multilateral reform, and climate equity.

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Bitget Launchpool Features GAIA with over 4.7M Tokens in Rewards

VICTORIA, Seychelles, July 29, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, has announced the feature of Gaia (GAIA) on its launchpool as well as a listing for spot trading. Gaia is a decentralized computing infrastructure that enables everyone to create, deploy, scale, and monetize their own AI agents. Trading for the GAIA/USDT pair will begin on 30 July 2025, 09:00 (UTC).

Bitget’s GAIA Launchpool campaign is offering 4,741,300 GAIA in total rewards. Eligible users can participate by locking BGB during the event, which runs from 30 July 2025, 09:00 to 1 August 2025, 09:00 (UTC). In the BGB locking pool, users can lock between 5 and 50,000 BGB, with maximum limits determined by their VIP tier, for a chance to earn a share of 3,858,300 GAIA.

Alongside the listing, Bitget will launch a CandyBomb campaign with 633,000 GAIA available in rewards. Of this, 211,000 GAIA will be allocated to the GAIA, BTC and BGB trading pool for new users, while 422,000 GAIA will be up for grabs in the GAIA trading pool for existing users. The campaign will run from 30 July 2025, 9:00 till 6 Aug 2025, 9:00 (UTC).

Bitget will also run an X Giveaway, where 750 qualified users will have the chance to win a share of 125,000 GAIA. The campaign runs from 30 July 2025, 9:00 to 1 August 2025, 9:00 (UTC). To participate, users must follow Bitget and Gaia on X, quote the giveaway post with the hashtag #GAIAxBitgetLaunchpool, tag a friend, sign up, deposit or trade GAIA on Bitget, and complete the form linked in the post.

In addition, a community campaign will run from 30 July 2025, 9:00 to 6 Aug 2025, 9:00 (UTC), offering another 125,000 GAIA to be shared among 750 qualified users. To join, users need to become members of both the Bitget Discord and BGB Holders Group, sign up, make a net deposit of over 100 USDT, and complete any GAIA/USDT spot trade.

Gaia is a decentralized AI network that enables users to host, own, and interact with autonomous AI agents in a secure and transparent environment. Built on blockchain technology, Gaia ensures each AI node operates independently while contributing to a broader, interconnected ecosystem. Users can deploy advanced models such as Qwen2 0.5B Instruct and customize them using personal or business data to create tailored AI services.

By prioritizing data sovereignty and privacy, Gaia introduces a new model for decentralized AI development and monetization. Its user–friendly infrastructure allows individuals to easily install node software, configure models, and participate in domain–based AI collaboration, unlocking new possibilities for innovation in the Web3 space.

Bitget continues to expand its offerings, positioning itself as a leading platform for cryptocurrency trading. The exchange has established a reputation for innovative solutions that empower users to explore crypto within a secure CeDeFi ecosystem.

With an extensive selection of over 800 cryptocurrency pairs and a commitment to broaden its offerings to more than 900 trading pairs, Bitget connects users to various ecosystems, including Bitcoin, Ethereum, Solana, Base, and TON. The addition of Gaia into Bitget’s portfolio marks a significant step toward expanding its ecosystem by embracing decentralized AI innovation, empowering users with greater control over data privacy, and supporting the next generation of AI–driven Web3 applications.

For more details on Gaia, visit here.

About Bitget

Established in 2018, Bitget is the world's leading cryptocurrency exchange and Web3 company. Serving over 120 million users in 150+ countries and regions, the Bitget exchange is committed to helping users trade smarter with its pioneering copy trading feature and other trading solutions, while offering real–time access to Bitcoin price, Ethereum price, and other cryptocurrency prices. Formerly known as BitKeep, Bitget Wallet is a leading non–custodial crypto wallet supporting 130+ blockchains and millions of tokens. It offers multi–chain trading, staking, payments, and direct access to 20,000+ DApps, with advanced swaps and market insights built into a single platform.

Bitget is driving crypto adoption through strategic partnerships, such as its role as the Official Crypto Partner of the World's Top Football League, LALIGA, in EASTERN, SEA and LATAM markets, as well as a global partner of Turkish National athletes Buse Tosun Çavuşoğlu (Wrestling world champion), Samet Gümüş (Boxing gold medalist) and İlkin Aydın (Volleyball national team), to inspire the global community to embrace the future of cryptocurrency.

Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. In the world of motorsports, Bitget is the exclusive cryptocurrency exchange partner of MotoGP™, one of the world’s most thrilling championships.

For more information, visit: Website | Twitter | Telegram | LinkedIn | Discord | Bitget Wallet

For media inquiries, please contact: [email protected]

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7730d634–b088–4a1c–b437–c1051b2dd570


GLOBENEWSWIRE (Distribution ID 1001120166)

Airstrikes in Myanmar Continue To Spread Fear, Devastate Lives

Four-year-old Ma July Phyo sits in a makeshift shelter in Mandalay with her mother, Ma Khin Phyo Kai, on April 2, 2025, five days after the deadly earthquake that struck Myanmar. Despite a ceasefire announced after the earthquake, the Tatmadaw continued its aerial attacks on local villages in its fight against armed resistance groups across the country, which continues to have deadly consequences for civilians. Credit: Maung Nyan/UNICEF

Four-year-old Ma July Phyo sits in a makeshift shelter in Mandalay with her mother, Ma Khin Phyo Kai, on April 2, 2025, five days after the deadly earthquake that struck Myanmar. Despite a ceasefire announced after the earthquake, the Tatmadaw continued its aerial attacks on local villages in its fight against armed resistance groups across the country, which continues to have deadly consequences for civilians. Credit: Maung Nyan/UNICEF

By Naomi Myint Breuer
UNITED NATIONS, Jul 29 2025 – In Myanmar, airstrikes occur almost daily. The phenomenon has become common since civil war broke out following the 2021 military coup that replaced the democratically elected National League for Democracy (NLD) with the Tatmadaw, Myanmar’s military. Several human rights organizations report that these airstrikes are disproportionately targeting civilians and harming lives.

The Tatmadaw uses airstrikes to fight armed resistance groups, such as the People’s Defense Forces (PDF), and regain control of areas from these groups, who control about 42 percent of the country’s territory, according to a BBC investigation published December 19, 2024.

After the March 28 earthquake, the Myanmar military and other groups involved declared a ceasefire, but attacks continued. Myanmar Witness reported 80 airstrikes occurred between March 28 and April 24, including in emergency-declared areas.

The Karen Human Rights Group reports that airstrikes are part of a broader attack on civilians in the country. Human rights groups and the UN found that the military disproportionately targets civilians with not only bombs but also mass executions of detained people and large-scale burning of homes.

Spokesman for the UN Secretary-General Stéphane Dujarric said these strikes are part of a pattern of attacks across the country.

“There are frequent reports of people being killed, injured or displaced by violence—as well as increasing attacks on civilian infrastructure,” he said at a July 16 press briefing.

Recent airstrikes, such as a July 11 strike on a monastery in Lin Ta Lu village, which killed 23 and injured 30, have redrawn attention to the country’s ongoing conflict. The Lin Ta Lu attack came weeks after the military began an offensive to reclaim territories controlled by resistance groups.

Public and religious sites have become targets. Myanmar Witness, a Centre for Information Resilience project investigating human rights in Myanmar, reported a trend of military operations hitting large civilian gatherings, with 109 cases of airstrikes damaging religious sites in 2024. A wedding held in a monastery in Magway Region was bombed on Feb. 25 after an invitation was posted on social media. They estimate that 11 people were killed.

“These trends highlight that religious and cultural sites are becoming increasingly at risk of complete destruction as a result of internal conflict in the country,” Myanmar Witness reported.

Dozens of schools have also been attacked, resulting in deaths and injuries of children. Many children have stopped attending school due to safety concerns. An aerial attack on a school in Oe Htein Kwin village in the Sagaing region on May 12 killed around 20 students and wounded dozens.

A Karen Education and Culture Department (KECD) school principal told the Karen Human Rights Group that all four of the school’s buildings were destroyed by bombs in a March 23, 2024 airstrike in a village in Doo Tha Htoo District. The cost of rebuilding is expensive, and they did not know whether anyone would be able to help rebuild it.

“I am sad to see the destruction of my school and worry that children will not be able to go to school…” the principal said. “I do not know how to describe my feelings of extreme fear. My whole heart breaks when I see the destroyed school. I cannot do anything now.”

Yadanar Maung, spokesperson for Justice For Myanmar, an activist group, accused international governments and corporations that fund, arm and train the Tatmadaw of empowering the military’s violent actions.

“The Myanmar military’s escalating violence against civilians, including through the intensification of airstrikes that target children, is not happening in a vacuum,” Maung told IPS.

Maung praised Airbus’ recent divestment from AviChina Industry & Technology Company Limited due to its links to the violence in Myanmar.

“Others must follow,” Maung said. “Governments must also act with stronger targeted sanctions on the military, its businesses, cronies and partners.”

The UN’s Independent Investigative Mechanism for Myanmar is investigating whether the Tatmadaw’s actions can be classified as crimes against humanity. The Mechanism called for information on aerial attacks for its investigation. They are prioritizing investigating attacks on children.

“Airstrikes that are indiscriminate or which target civilians may be war crimes or crimes against humanity,” the Mechanism wrote.

The airstrikes make it difficult for the UN to deliver humanitarian assistance to people in need. Currently, one in three people in Myanmar face acute hunger, according to Dujarric.

“We urgently, and once again, call on all parties to respect human rights and international humanitarian law,” he said.

Myanmar receives far less attention than other regions undergoing conflict and distress. Without the same level of attention, the war cannot end and the humanitarian situation will not be alleviated. Myanmar Witness said that it is important to continue reporting on the situation in Myanmar so as to keep other nations updated. They said the situation is complex and can be difficult for foreigners to understand.

“The international community isn’t as aware of this continuing internal conflict due to other important conflicts taking media attention, particularly in Western news outlets,” Myanmar Witness wrote to IPS. “It is important to continuously push to get news about Myanmar out to the international community as much as we can.”

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById({js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Les Données de l'Étude Pivot DREAM de Nyxoah publiées dans le Journal of Clinical Sleep Medicine

Les Données de l'Étude Pivot DREAM de Nyxoah publiées dans le Journal of Clinical Sleep Medicine

Mont–Saint–Guibert, Belgique – 28 juillet 2025, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui que les données de son étude pivot DREAM ont été publiées en ligne dans le Journal of Clinical Sleep Medicine. L'étude pivot DREAM présente des résultats complets de sécurité et d'efficacité sur 12 mois, qui ont étayé la demande d'autorisation de mise sur le marché (PMA) de la Société auprès de la FDA. La publication “peer–reviewed” fournit une analyse détaillée des performances du système Genio® à travers de multiples critères d'évaluation clinique.

La publication révèle de nouvelles données sur l'utilisation de l'appareil et la satisfaction des patients qui ne figuraient pas dans les annonces précédentes de la Société. Ces résultats supplémentaires montrent que l'utilisation nocturne de l'appareil a été supérieure à 4 heures pendant plus de 70 % des nuits chez 84,3 % des participants ayant rempli un journal au cours des 3 mois précédant la visite à 12 mois. Dans l'ensemble, l'appareil a été utilisé plus de 70 % des nuits par 85,9 % des participants.

La publication indique également que 90 % des patients se sont déclarés satisfaits de la thérapie. En outre, les données montrent que le score de ronflement des patients1 est passé de 83,5 % au départ à 30,4 % après 12 mois.

“L'étude DREAM a démontré l'efficacité de la stimulation bilatérale du nerf hypoglosse à l'aide de Genio pour le traitement de l'apnée obstructive du sommeil,” a déclaré B. Tucker Woodson, MD, Chief, Professor – Medical College of Wisconsin et Investigateur principal de l'étude DREAM. “Genio a démontré un effet important dans la réduction du fardeau de la maladie et l'amélioration de la qualité de vie en réduisant de manière significative la quantité d’apnées–hypopnées, encourageant l'adhésion et la satisfaction du patient. La conception de Genio, centrée sur le patient, et la stimulation bilatérale du HGNS constituent une avancée importante dans le traitement des patients souffrant d'AOS qui ne parviennent pas à utiliser la PPC ou qui refusent de l'utiliser.”

“Ces résultats récemment publiés correspondent exactement à ce que nous attendions”, a déclaré Olivier Taelman, CEO de Nyxoah. “La grande satisfaction des patients et l’adhésion à la thérapie confirment notre conviction que la conception sans sonde et à alimentation externe de Genio répond aux besoins réels des patients. L'amélioration significative de la qualité du sommeil des partenaires montre l'impact plus large que notre technologie peut avoir sur les patients souffrant d'AOS et leurs familles.”

La publication inclut des données précédemment annoncées démontrant que l'étude a atteint ses objectifs co–primaires, à savoir le taux de répondeurs à l'IAH à 12 mois, selon le critère de Sher, et le taux de répondeurs à l'indice de désaturation en oxygène (IDO), tous deux en intention de traiter (ITT). Dans l'étude pivot DREAM U.S., 115 patients ont reçu l'implant Genio® et ont été inclus dans l'analyse de sécurité. Ces patients présentaient un IAH moyen de 28,0, un IDO moyen de 27,0 et un indice de masse corporelle moyen de 28,5 au début de l'étude. Après 12 mois, 73 sujets ont été considérés comme répondeurs à l'IAH, selon le critère de Sher, soit un taux ITT de répondeurs à l'IAH de 63,5 % (p=0,002), et 82 sujets ont été considérés comme répondeurs à l'IDO, soit un taux de répondeurs à l'IDO de 71,3 % (p<0,001). Les résultats en matière de sécurité étaient conformes à ceux d'autres thérapies de neuromodulation, avec 11 événements indésirables graves, ou EIG, chez dix sujets, soit un taux d'EIG de 8,7 %. Sur les 11 EIG, trois étaient liés au dispositif et il y a eu trois explantations.

La publication inclut également des données précédemment annoncées démontrant une réduction similaire de l'IAH en position dorsale et non dorsale. La stimulation bilatérale Genio a entraîné une réduction médiane cliniquement significative de 66,6 % de l'IAH en décubitus dorsal à 12 mois par rapport à la valeur de référence. Cette réduction est à comparer à une réduction médiane de l'IAH à 12 mois de 70,8 % dans toutes les positions de sommeil.

En ce qui concerne les critères d'évaluation secondaires rapportés à l'ISSS, les sujets ont montré des améliorations significatives de la qualité de vie. Plus précisément, une augmentation moyenne de 2,3 points a été observée dans l'évaluation du questionnaire sur les résultats fonctionnels du sommeil (FOSQ). En outre, le score de somnolence d'Epworth a été réduit de 3,4 points en moyenne par rapport à la situation initiale.

A propos de Nyxoah

Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La vision de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

À la suite de la finalisation probante de l’étude BLAST OSA, le système Genio® a reçu le marquage européen CE en 2019. Nyxoah a réalisé avec succès deux IPO : l’une sur Euronext Bruxelles en septembre 2020 et l’autre sur le NASDAQ en juillet 2021. Grâce aux résultats positifs de l'étude BETTER SLEEP, Nyxoah a reçu le marquage CE pour l’extension de ses indications thérapeutiques aux patients souffrant de collapsus concentrique complet (CCC), pour lesquels les thérapies concurrentes sont actuellement contre–indiquées. En outre, la Société a annoncé les résultats positifs de l'étude pivot DREAM IDE.

Pour plus d’informations, visitez www.nyxoah.com

Attention – Marquage CE depuis 2019. Dispositif de recherche aux États–Unis. Limité à un usage expérimental aux États–Unis par la loi fédérale américaine.

Déclarations Prospectives

Certaines déclarations, croyances et opinions contenues dans le présent communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, des administrateurs ou de la direction de la Société concernant le système Genio®, les études cliniques prévues et en cours sur le système Genio®, les avantages potentiels du système Genio®, les objectifs de Nyxoah concernant le développement, la voie réglementaire et l'utilisation potentielle du système Genio®, l'obtention de l'approbation de la FDA, l'achèvement satisfaisant de l'examen des installations de fabrication, des méthodes et des contrôles, et le calendrier prévu pour ce qui précède, l'entrée sur le marché américain, ainsi que les résultats d'exploitation, la situation financière, les liquidités, les performances, les perspectives, la croissance et les stratégies de la Société. De par leur nature, les déclarations prévisionnelles impliquent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou les événements réels diffèrent matériellement de ceux exprimés ou sous–entendus dans les déclarations prévisionnelles. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence négative sur les résultats et les effets financiers des plans et des événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section « Facteurs de risque » du rapport annuel de la Société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2024, déposé auprès de la Securities and Exchange Commission (« SEC ») le 20 mars 2025, et des rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent de manière significative de tout développement anticipé. Les déclarations prospectives contenues dans le présent communiqué de presse concernant des tendances ou des activités passées ne constituent pas des garanties de performances futures et ne doivent pas être considérées comme une déclaration selon laquelle ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements peuvent ne pas être représentatifs des résultats ou développements des périodes futures. Aucune déclaration ou garantie n'est donnée quant à l'exactitude ou à la justesse de ces déclarations prospectives. En conséquence, la Société décline expressément toute obligation ou tout engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement des attentes ou d'un changement des événements, conditions, hypothèses ou circonstances sur lesquels ces déclarations prospectives sont basées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni les dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces déclarations prospectives sont exemptes d'erreurs et n'acceptent aucune responsabilité quant à l'exactitude future des déclarations prospectives contenues dans ce communiqué de presse ou quant à la survenance effective des développements prévus. Vous ne devriez pas accorder une confiance excessive aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contacts :

Nyxoah
John Landry, CFO
[email protected]

Medias
Aux États–Unis
FINN Partners – Alyssa Paldo
[email protected]

International / Allemagne
MC Services – Anne Hennecke
nyxoah@mc–services.eu

Belgique / France
Backstage Communication – Gunther De Backer
[email protected]


1 Parmi ceux qui ont déclaré que leur partenaire de lit avait quitté la chambre, qu'il avait ronflé très fort ou fort

Pièce jointe


GLOBENEWSWIRE (Distribution ID 1001120139)

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

Mont–Saint–Guibert, Belgium – July 28, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that data from its DREAM pivotal study was published online in the Journal of Clinical Sleep Medicine. The DREAM pivotal study presents comprehensive 12–month safety and efficacy results that supported the Company's PMA submission to the FDA. The peer–reviewed publication provides detailed analysis of the Genio® system's performance across multiple clinical endpoints.

The publication reveals new data on device usage and patient satisfaction that was not included in the Company's previous announcements. These additional findings show that nightly device usage was greater than 4 hours in more than 70% of nights in 84.3% of participants completing diary entries in the 3 months preceding the 12–month visit. Overall, the device was used over 70% of the nights by 85.9% of the participants.  

 The publication also reports 90% of patients expressed satisfaction with the therapy. Additionally, data shows that a patient’s snoring score1 was reduced from 83.5% at baseline to 30.4% at 12 months.

“The DREAM study demonstrated efficacy of bilateral hypoglossal nerve stimulation using Genio for the treatment of obstructive sleep apnea,” said B. Tucker Woodson, MD, Chief, Professor – Medical College of Wisconsin and Principal Investigator of the DREAM study. “Genio demonstrated a strong effect in reducing disease burden and improving quality of life by significantly reducing the apnea hypopnea burden encouraging patient adherence and satisfaction. Genio's patient–centric design and bilateral HGNS stimulation offer an exciting advancement in treatment of OSA patients who fail or refuse CPAP.”

“These newly published outcomes are exactly what we expected to see,” said Olivier Taelman, CEO of Nyxoah. “The high patient satisfaction and consistent usage patterns validate our belief that Genio's leadless, externally powered design addresses real patient needs. The significant improvement in bedpartner sleep quality shows the broader impact our technology can have on OSA patients and their families.”

The publication included previously announced data demonstrating that the study achieved its co–primary endpoints of 12–month AHI responder rate, per the Sher criteria, and Oxygen Desaturation Index (ODI) responder rate, both on an Intent–To–Treat (ITT) basis. In the DREAM U.S. pivotal study, 115 patients received the Genio® implant and were included in the safety analysis. These patients had a mean AHI of 28.0, mean ODI of 27.0 and mean body mass index of 28.5 at baseline. At 12 months, 73 subjects were determined to be AHI responders, per the Sher criteria, resulting in an ITT AHI responder rate of 63.5% (p=0.002), and 82 subjects were determined to be ODI responders, resulting in an ODI responder rate of 71.3% (p<0.001). Safety results were in line with other neuromodulation therapies, with 11 serious adverse events, or SAEs, in ten subjects resulting in an SAE rate of 8.7%. Out of the 11 SAEs, three were device related, and there were three explants.

 The publication also included previously announced data demonstrating similar AHI reduction in supine and non–supine positions. Genio bilateral stimulation resulted in a clinically meaningful 66.6% median reduction in supine AHI at 12 months compared with baseline. This reduction compares to a median 12–month AHI reduction of 70.8% across all sleeping positions.

 With respect to secondary endpoints reported at ISSS, subjects demonstrated significant improvements in quality–of–life outcomes. Specifically, a mean increase of 2.3 points was observed in the Functional Outcomes of Sleep Questionnaire (FOSQ) assessment. Additionally, the Epworth Sleepiness Score was reduced by a mean of 3.4 points from baseline.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States

FORWARD–LOOKING STATEMENTS
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; receipt of FDA approval; satisfactory completion of a manufacturing facilities, methods and controls review, and the anticipated timing of the foregoing; entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward–looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward– looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts: Nyxoah
John Landry, CFO
[email protected]

For Media

In United States
FINN Partners – Glenn Silver
[email protected]

In International/Germany
MC Services – Anne Hennecke nyxoah@mc–services.eu

In Belgium/France
Backstage Communication – Gunther De Backer [email protected]


1   In those that reported bedpartner leaving the room, very loud or loud snoring

Attachment


GLOBENEWSWIRE (Distribution ID 1001120139)

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company’s proposal that the NDA marketing application filing for EB613 would be supported by a single multinational, randomized, double–blind, placebo–controlled, 24 month phase 3 study in women with postmenopausal osteoporosis, where change in total hip BMD is evaluated as the primary endpoint, and incidence of new or worsening vertebral fractures is evaluated as the key secondary endpoint. This marks a shift from precedent placebo–controlled phase 3 studies of new osteoporosis drugs which required incidence of fracture as the primary endpoint.

“This regulatory update is a major milestone for Entera and the entire osteoporosis community,” said Miranda Toledano, CEO of Entera. “Our alignment with the FDA reflects the strength of our data and collaborative discussions. Importantly, it allows us to advance our clinical development program without having to wait for FDA’s qualification of the Study to Advance Bone Mineral Density as a Regulatory Endpoint (SABRE), which is still expected this year. We thank the FDA and the Review Team at the Division of Endocrinology for their constructive approach. We also thank the SABRE team for paving the path to innovation for osteoporosis treatment,” said Toledano.

“Osteoporosis afflicts more women than heart attack, stroke and breast cancer combined. Over 200 million women globally are estimated to have osteoporosis and remain vastly undertreated, despite efficacious injectable anabolic (bone forming) treatments. One in two women over the age of 50 will suffer a fracture due to osteoporosis. No new drug for osteoporosis has been approved by FDA since 2019; and innovation has stalled for close to a decade due to the size, duration, cost and ethical constraints associated with fracture endpoint studies. In a silent disease, patient and clinician access to novel and alternative forms of validated mechanisms of action is important. We are developing EB613 as the first oral, once–daily anabolic tablet treatment to potentially serve this unmet medical need. EB613 is intended to increase skeletal mass, improve bone microarchitecture and reduce the risk of fracture,” said Miranda Toledano, CEO of Entera.

About EB613

Substantial evidence supports the efficacy of anabolic therapies over bisphosphonates for lowering fracture risk in osteoporosis patients at high risk. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. EB613 (oral PTH (1–34), teriparatide), is being developed as the first oral, once–daily anabolic tablet treatment for osteoporosis. EB613 completed a phase 2, 6–month, 161–patient, placebo–controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose–proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increased lumbar spine, total hip, and femoral neck BMD. The effects of EB613 on trabecular and cortical bone using 3D–DXA showed increases with EB613 compared with placebo in a variety of indices, including integral volumetric BMD and trabecular volumetric BMD, cortical thickness, and cortical surface BMD. Mechanistically, the findings suggest that bone strengthening, and fracture resistance may occur rapidly with EB613. Furthermore, the data are consistent with those of published subcutaneous teriparatide at the 6–month time point. Further abstracts have been submitted to ASBMR and NAMS 2025 conferences.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline of first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo–controlled, dose–ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP–2 peptide as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

About SABRE

The Study to Advance BMD as a Regulatory Endpoint (SABRE) initiative, which started as a public private partnership sponsored by the FNIH in 2013, has amassed the strongest evidence to date that treatment–related gains in Bone Mineral Density (BMD) reliably and quantitatively predict fracture–risk reduction. In November 2023, the SABRE team submitted a full qualification package to FDA’s Biomarker Division as part of the Drug Development Tool Biomarker Qualification Pathway to potentially qualify BMD as a surrogate endpoint to fracture; in March 2024, the FDA Biomarker Division indicated to the SABRE project team that a decision would be issued within 10 months. The single most important predictor of osteoporotic fractures in postmenopausal women without a previous fracture is BMD. Treatment guidelines in the U.S. strongly recommend pharmacologic therapy for patients with a BMD T–score of –2.5 or lower in the spine, femoral neck, total hip. SABRE final FQP meta–analysis included data from 22 randomized, placebo–controlled trials (63,000 participants across seven drug classes) and showed that treatment–related gains in total–hip BMD explain 72% of the observed fracture–risk reduction. The R2 for this correlation was 0.73—double the correlation between blood pressure and stroke (R² = 0.37), which is the well accepted basis for the value of antihypertensive therapy.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this presentation are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10–K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this presentation. The information in this presentation is provided only as of the date of this presentation, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9501141)

WeRide Robotaxi Secures Autonomous Driving Permit in Saudi Arabia, Products Now Licensed in Six Countries

RIYADH, Saudi Arabia, July 28, 2025 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD), a global leader in autonomous driving technology, has announced today that its Robotaxi was granted Saudi Arabia's first Robotaxi autonomous driving permit, making it the world's only technology company with products holding autonomous driving permits in six countries: Saudi Arabia, China, the UAE, Singapore, France, and the US.

WeRide's Robotaxi in Riyadh, Saudi Arabia

With this permit, WeRide is authorized to operate an autonomous vehicle (AV) business and deploy Robotaxis nationwide in Saudi Arabia, starting with its pilot operations in Riyadh with Uber and local partner Ai Driver.

Launched earlier this month, the pilot covers King Khalid International Airport and several key locations throughout Riyadh, including major highways and selected city center destinations. A full–scale commercial Robotaxi service is expected to launch by end–2025 through a partnership between WeRide and Uber.

WeRide's Robotaxi was granted the permit at an official ceremony last week, attended by His Excellency Eng. Saleh bin Nasser Al–Jasser, Minister of Transport and Logistics Services and Chairman of the Transport General Authority (TGA); Jennifer Li, CFO and Head of International at WeRide; and other senior Saudi government officials.

WeRide is the first AV technology company whose Robotaxi has completed the TGA's Regulatory Sandbox for AV Piloting in Saudi Arabia. The approval process, conducted in coordination with multiple government agencies, includes rigorous testing, assessments, and technology validation to secure the Robotaxi autonomous driving permit, to ensure the highest standards of safety and performance.

“This permit marks a major step in our global expansion, enabling us to scale Robotaxi services and unlock new commercial opportunities in Saudi Arabia. It drives large–scale deployment, unlocks new revenue streams, and reinforces our commitment to making autonomous mobility a reality worldwide. We thank the TGA for supporting our vision for safer, smarter transportation at scale,” said Jennifer Li, CFO and Head of International at WeRide.

This announcement follows WeRide’s entry into Saudi Arabia in May 2025. In addition to its Robotaxi plans, WeRide has been testing and operating its Robobus in key locations including King Fahad Medical City, Aramco residential communities, AlUla, and the Ritz–Carlton, Riyadh. Its Robosweeper S1 is also in operation at King Fahad Medical City, Riyadh Second Health Cluster, marking the first monetized autonomous sanitation project in both Saudi Arabia and the wider Middle East.

Beyond Saudi Arabia, WeRide has been rapidly expanding across the region in the last few months. Its Robotaxis are currently undergoing fully driverless Robotaxi testing in Abu Dhabi — the first deployment of its kind in Middle East — and will also soon extend its Robotaxi service to Dubai.

About WeRide
WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 30 cities across 10 countries. We are also the first and only technology company whose products have received autonomous driving permits in six markets: China, France, Saudi Arabia, Singapore, the UAE, and the US. Empowered by the smart, versatile, cost–effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named in Fortune Magazine’s 2024 “The Future 50” list.

Media Contact
[email protected]

Safe Harbor Statement
This Report (including its exhibit) contains statements that may constitute “forward–looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward–looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward–looking statements. Forward–looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s and Uber’s filings with the U.S. Securities and Exchange Commission. All information provided in this Report is as of the date of this Report. Neither WeRide nor Uber undertakes any obligation to update any forward–looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68d8e7b7–f0e9–4056–a03e–d76112c629d6


GLOBENEWSWIRE (Distribution ID 9501329)

Violence Escalates in Sudan as Humanitarian Aid Struggles to Meet Growing Needs

A Sudanese mother and her child at a shelter in Tawila, North Darfur. Credit: UNICEF/Mohammed Jamal

By Oritro Karim
UNITED NATIONS, Jul 28 2025 – Earlier this month, Sudanese civilians began facing a considerable escalation of hostilities, with the most recent attacks from the Rapid Support Forces (RSF) and the Sudanese Armed Forces (SAF) claiming dozens of lives. Amid a rapidly growing scale of needs and an overwhelming lack of funding, the United Nations (UN) and its partners have struggled to deliver adequate amounts of humanitarian aid.

On July 23, the RSF coordinated an attack on the Brima Rashid area in West Kordofan State, with combatants entering on assault vehicles and indiscriminately firing at homes and a market. According to the Office for the Coordination of Humanitarian Affairs (OCHA), this attack killed over 30 people and severely injured 40 others, with a significant amount of these casualties being women and young children.

“Medical sources say many of the wounded need urgent surgical care,” said Farhan Haq, the UN Deputy Spokesperson for the Secretary-General at a press briefing. “OCHA stresses that events in Brima Rashid underscore the growing risks facing civilians in the Kordofan region and the urgent need for a cessation of hostilities, protection of civilians, and safe, sustained access to humanitarian assistance and services.”

This is just the latest in a series of attacks that have marked a sharp rise in violence across the Kordofan and North Darfur regions. Between July 10 and 13, the Rapid Support Forces (RSF) launched a series of attacks on North Kordofan’s Bara locality. The Office of the United Nations High Commissioner of Human Rights (OHCHR) estimates that these attacks resulted in 60 civilian deaths, while figures from independent civil society groups estimate up to 300 deaths.

Concurrently, the Sudanese Armed Forces (SAF) launched a series of attacks on the Al Fula and Abu Zabad villages in West Kordofan State, including an airstrike on a school that was being used as a makeshift displacement shelter, killing over 20 people. On July 17, the SAF also targeted a family in an airstrike in Bara, killing at least 11 civilians. Additional attacks and civilian casualties were recorded in El Fasher and the Abu Shouk camp.

“An escalation of hostilities in North Darfur and Kordofan will only further aggravate the already severe risks to civilians and the dire humanitarian situation in a conflict that has already wrought untold suffering on the Sudanese people,” said the UN High Commissioner for Human Rights Volker Türk. “I urge those with influence to act to prevent such an escalation, and to ensure that both parties uphold their obligations under international law, including on the protection of civilians and civilian infrastructure.”

According to the International Organization for Migration (IOM), as of July 14 there have been over 3,400 internal displacements as a result of the recent attacks in North Kordofan. These numbers were further inflamed by a period of heavy rain and flooding from July 14 and 15, resulting in 400 additional displacements.

The majority of these displaced individuals are currently residing with host communities and face a dire lack of access to basic services, such as food, water, shelter, and healthcare. The Office for the Coordination of Humanitarian Affairs (OCHA) estimates that approximately 30 million people are in dire need of humanitarian assistance and protection, which is roughly half of Sudan’s population.

Conditions are particularly dire in the Tawila locality of North Darfur, which currently hosts over 560,000 internally displaced civilians. OCHA’s partners report that a significant amount of water, sanitation, and hygiene (WASH) needs are not being met, as there is a critically low ratio of one latrine for every 150 people. Humanitarian experts have expressed concern due to the rising cases of cholera in Tawila. According to figures from Sudan’s Health Ministry, there have been over 1,300 cases of cholera and 18 related deaths recorded across 35 localities, with 519 of these cases being recorded in Tawila alone.

Additionally, Sudan’s hunger crisis has taken a considerable turn for the worse in recent weeks, with food prices having skyrocketed immensely. According to OCHA, South Darfur had been hit particularly hard, with flooding cutting off critical supply routes from Chad and the north of Sudan. Over the course of a month, the price of wheat has risen by 31 percent and the price of sugar has risen by 21 percent, pushing these essential items out of reach for thousands.

Figures from the World Food Programme (WFP) show that famine has been confirmed in 10 states across Sudan, with nearly half of the population facing extreme levels of hunger. OCHA projects that women are disproportionately impacted by the hunger crisis, with rates of food insecurity among female-headed households nearly doubling from 14 percent in 2024 to 26 percent in 2025.

The persistence of widespread hunger and disease across Sudan is a testament to Sudan’s fragile healthcare system. According to OCHA, heightened insecurity has resulted in the closures of over 32 health facilities in Sudan. The centers that are still functional face a critical shortage of essential supplies such as vaccines, medication, and surgical equipment. It is estimated that thousands lack access to life-saving care.

On July 25, the United Nations High Commissioner for Refugees (UNHCR) and IOM released a joint report that analyzed the conditions facing Sudanese refugees who had returned home after fleeing to Egypt and South Sudan. According to the report, roughly 320,000 refugees had returned to Sudan throughout the past year, with many struggling to access basic services .

“Without urgent action, people will be coming back to cities that are in ruins,” said Abdallah Al Dardari, Director of the Regional Bureau for Arab States in the United Nations Development Programme (UNDP). “We are in a race against time to clear the rubble and provide water, power and healthcare.”

The report underscores the vast array of dangers that await Sudanese returnees, including the risk of injury or death from unexploded ordnance, high rates of gender-based and sexual violence toward women and girls, as well as a lack of psychosocial support services for traumatized individuals.

The UN and its partners remain hopeful that the current influx of returnees is an indication of stabilization in Sudan. “Those heading home are not passive survivors. They are vital to Sudan’s recovery,” said Othman Belbeisi, IOM Regional Director for the Middle East and North Africa. “Yes, the humanitarian situation is dire, but with the right support, returnees can revive local economies, restore community life and foster hope where it’s needed most”.

Despite this, increased funding for humanitarian affairs and a sustainable end to hostilities is the only way to ensure lasting peace and stability in Sudan. The UN projects that approximately USD 4.2 billion dollars is needed to keep up aid operations in Sudan for the next year. However, only 23 percent of the required funds have been met, indicating that services may need to be scaled back next year.

“More than evidence of people’s desire to return to their homeland, these returns are a desperate call for an end to the war so that people can come back and rebuild their lives,” said Mamadou Dian Balde, UNHCR Regional Refugee Coordinator for the Sudan crisis, shortly after returning from Khartoum and Wadi Halfa at the border with Egypt. “Not only do they mark a hopeful but fragile shift, they also indicate already stretched host countries under increasing strain. We urge stronger international solidarity with the Sudanese people uprooted by this horrifying war and with the countries that have opened their doors to them.”

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Mining on the Rise as Clean Energy Demands Shifts Global Commodity Exports

Oil tankers entering and departing a busy port. Credit: Unsplash/Ramona Flwrs

By Maximilian Malawista
NEW YORK, Jul 28 2025 – Two-thirds of the developing world, or ninety-five out of 143 economies, are dependent on commodities for export value, making up 60 percent of their merchandise exports. For the least developed world, this number rises to 80 percent, leaving entire nation’s revenue vulnerable to price swings, fiscal shocks, and evolving trade compositions. Hidden behind the numbers lies a deeper transformation, one disrupting fossil fuel trade, triggering a higher reliance on mineral exports, particularly on mining essential for green technologies.

In 2024, during a special climate panel, on critical energy transition minerals, UN Secretary-General António Guterres remarked, “A world powered by renewables is a world hungry for critical minerals. For developing countries, critical minerals are a critical opportunity – to create jobs, diversify economies, and dramatically boost revenues. But only if they are managed properly.”

Guterres signaled a clear message that this change can indeed boost economies and create jobs, especially in the places which need it most, but only if those countries are then willing to invest in diversification strategies through proper economic management.

At this year’s UN High Level Political Forum Guterres reaffirmed his stance on July 22, stating: “Fossil fuels are outdated. The sun is rising on a new era − the era of clean energy.” Guterres present a six-point action plan forward, which would phase out fossil fuels and secure energy access to all, by outlining methods of financing green transition.

A shift in the tides: oil to ore

Between 2012-2014 and 2021-2023, the share of commodity exports in of global trade have slightly declined, from 35.5 percent to 32.7 percent. At the same time, overall merchandise trade grew by 25.6 percent, with commodity exports growing by 15.5 percent. This 10 percent gap accounts for a 619 billion dollar shortfall due to declining and stagnating energy exports, which currently dominate the commodity trade.

Energy exports once led the commodity trade but are now showing obvious signs of stagnation and future decline. From 2021 to 2023, global energy exports amounted to 3.16 trillion on average, slightly decreasing 1.3 percent from the 2012-2014. The acceleration of renewable energy projects and the UN’s 2030 Agenda have been main proponents in this, driving down the reliance on oil and coal, and improving energy efficiency through global investment in green technologies.

Western Asia, once a dominant region in energy exports, particularly oil, saw its share fall from 31.3 percent to 24.7 percent over the past decade. Russia, once the world’s top energy exporter saw its export value drop by 26.6 percent.

However, in this same period, the United States became the world’s leading energy exporter, driven by its massive quantities of liquefied natural gas and shale oil mining. This shift too even reflects a greener transition, as liquefied natural gas is seen increasingly as a bridge to clean energy, as it presents cleaner effects on the environment, and is overall considered cleaner than oil and coal by a large margin.

In contrast to this overall decline in energy demand, mining exports have been surging. In Asia and Oceania, the regions’ share grew from 33.8 percent to 37.6 percent. Looking at Australia alone, they grew their mining export value from USD 105.7 billion to USD 171 billion due to higher demand from China and other global consumers for metals like copper, cobalt, and lithium. These materials are necessary for solar panels, wind turbines and electric car batteries, which are all considered essential components to a green economy.

Suppliers of the green future: Africa

While much of the world is expanding looking towards the future, Africa is still largely behind in development, creating lags in green agendas. Most of the continent lacks basic access to electricity. Africa is home to twenty of the world’s thirty-three mining export-dependent economies, making them the provider of many materials for green technologies, but not the constructors.

In Western and Eastern Africa, these mining exports make up 65 percent and 57 percent of all merchandise exports. Southern Africa is also particularly reliant, with nations like Botswana presenting mining exports of 91.5 percent. This lack of diversification makes African economies extremely vulnerable to supply chain shifts and price volatility, especially in the event of value chain swaps. Even in countries where mining is not as prevalent like Nigeria, Algeria and Angola, the lowering of oil prices by 20 percent in economies with an 80 percent export value on energy, shows early signs of dangerous fiscal dependency on a lacking financial flow.

The inevitable shift

Secretary-General of UN Trade and Development (UNCTAD) Rebecca Grynspan said: “There is now an opportunity to leverage these new commodities to update our trade regime, promote structural diversification and turn the tide of commodity dependence once and for all.”

The clean energy shift is not theory, it is happening real time and its reshaping supply chains fast. Countries like the U.S. and Australia have successfully adapted their economies to this shift, preparing for a new landscape of green domination. The rise in mining exports supports a demand from advanced economies needing critical minerals, but this financial flow for the exporting countries might not stay forever, especially if more competitors break into the market driving down the price further and further: much like what is happening to oil. A country’s path to clean energy now lies as an indicator of working economic models and the ablution of outdated financial flows.

IPS UN Bureau Report

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);